SCHEMBL168901

SCHEMBL168901

N#Cc1cc(F)ccc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
KEAP1 Q14145 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39
PIK3CD O00329 1/20 0.38
TRPV4 Q9HBA0 1/20 0.38
KHK P50053 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CSNK2A1 P68400 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30262619 1.00 ALDH1A1 (0.50) ALDH1A1KEAP1MEN1KMT2AKDM4E
SCHEMBL3574934 0.84 CYP11B1 (0.50) ALDH1A1MEN1KMT2AKDM4ECYP1A2
SCHEMBL404482 0.82 ALDH1A1 (0.44) ALDH1A1KEAP1MEN1KMT2AKDM4E
SCHEMBL28967099 0.81 ALDH1A1 (0.54) ALDH1A1KEAP1MEN1KMT2AKDM4E
SCHEMBL5368384 0.79 MAOA (0.44) ALDH1A1MEN1KMT2AKDM4ECYP1A2
SCHEMBL3879887 0.79 TAAR1 (0.55) MEN1KMT2AKDM4ECYP11B1CYP11B2
SCHEMBL573864 0.78 MAOB (0.53) ALDH1A1KDM4ETRPV4MAOAMAOB
SCHEMBL22134762 0.77 ALDH1A1 (0.50) ALDH1A1KEAP1CYP1A2GAAHTT
SCHEMBL30182222 0.77 ALDH1A1 (0.50) ALDH1A1KEAP1CYP1A2GAAHTT
SCHEMBL6150149 0.77 ALDH1A1 (0.50) ALDH1A1KEAP1GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119176746-B Method for preparing bisphenol A and heterocyclic compound by using waste PC 浙江大学 2025-05-30 CN claimed
CN-119176746-A Method for preparing bisphenol A and heterocyclic compound by using waste PC 浙江大学 2024-12-24 CN claimed
CN-118440013-A Preparation method of quinazoline diketone compound 安顺学院 2024-08-06 CN claimed
CN-114380718-B Acylation method of aniline compound 河南农业大学 2022-09-30 CN claimed
CN-114380718-A Acylation method of aniline compound 河南农业大学 2022-04-22 CN claimed
CN-113354558-B Preparation method of 2-amino-5-fluorobenzonitrile 无锡双启科技有限公司 2022-03-11 CN claimed
CN-113354558-A Preparation method of 2-amino-5-fluorobenzonitrile 无锡双启科技有限公司 2021-09-07 CN claimed
CN-108640919-B Matrine derivative and sophoridine derivative containing aryl amidine or aminoquinoline structure and preparation method thereof 广西大学 2020-09-08 CN claimed
CN-117177975-B Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof 蒙特利尔大学 2026-05-19 CN disclosed
CN-122055367-A 5-Oxo-4, 5-dihydroimidazo [1,5-a ] quinazoline compounds as PI3K [ alpha ] inhibitors 皮卡维森治疗学股份有限公司 2026-05-15 CN disclosed
EP-4720060-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2026-04-08 EP disclosed
US-12509431-B2 1,4-dihydroquinazolinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-12-30 US disclosed
US-20250361213-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2025-11-27 US disclosed
EP-4594307-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2025-08-06 EP disclosed
EP-1308513-A1 USE OF POLYPEPTIDE Takeda Chemical Industries, Ltd. (JP) 2003-05-07 EP disclosed
EP-1262195-A1 VASOACTIVE AGENTS Takeda Chemical Industries, Ltd. (JP) 2002-12-04 EP disclosed
US-6433174-B1 Process for producing novel naphthyridine derivatives NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2002-08-13 US disclosed
EP-1142892-A1 PROCESSES FOR THE PREPARATION OF NOVEL NAPHTHYRIDINE DERIVATIVES Nippon Kayaku Kabushiki Kaisha (JP) 2001-10-10 EP disclosed
EP-0519307-A2 Tetracyclic Imidazodiazepines F. HOFFMANN-LA ROCHE AG (CH) 1992-12-23 EP disclosed
US-RE28939-E MUSCLE RELAXANTS, ANALGESICS SMITHKLINE CORPORATION (US) 1976-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509431-B2 1,4-dihydroquinazolinone compounds and uses thereof TNNT2, TNNI3, TNNC1 ALDH1A1 716/4885KEAP1 1991/4885MEN1 3410/4885
US-20250361213-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, SDHA ALDH1A1 780/4885KEAP1 654/4885MEN1 2996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.